Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia

Published:2016-07-20 Issue:11 Volume:63 Page:1943-1948
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Sun Weili¹²,Orgel Etan¹²,Malvar Jemily¹,Sposto Richard¹²,Wilkes Jennifer J.³,Gardner Rebecca⁴,Tolbert Vanessa P.⁴,Smith Alison²,Hur Minjun⁵,Hoffman Jill²⁶,Rheingold Susan R.³,Burke Michael J.⁷,Wayne Alan S.¹²

Affiliation:

1. Children's Center for Cancer and Blood Diseases; Children's Hospital Los Angeles; California

2. Keck School of Medicine; USC-Norris Comprehensive Cancer Center; University of Southern California; Los Angeles California

3. Department of Pediatrics, Division of Oncology; The Children's Hospital of Philadelphia; Philadelphia Pennsylvania

4. Department of Pediatrics; Seattle Children's Hospital; Seattle Washington

5. School of Medicine; St. Louis University; St. Louis Missouri

6. Infectious Disease; Children's Hospital Los Angeles; California

7. Pediatric Leukemia and Lymphoma; Children's Hospital of Wisconsin; Medical College of Wisconsin; Milwaukee Wisconsin

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.26129/fullpdf

Reference31 articles.

1. Long-term results of the Pediatric Oncology Group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the Children's Oncology Group;Salzer;Leukemia,2010

2. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group;Hunger;J Clin Oncol,2012

3. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study;Nguyen;Leukemia,2008

4. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study;Ko;J Clin Oncol,2010

5. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group Study[corrected];Raetz;J Clin Oncol,2008

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia;Haematologica;2024-05-10

2. INSPIRED Symposium Part 4A: Access to CAR T Cell Therapy in Unique Populations with B Cell Acute Lymphoblastic Leukemia;Transplantation and Cellular Therapy;2024-01

3. Treating relapsed B cell-precursor ALL in children with a setting-adapted mitoxantrone-based intensive chemotherapy protocol (TMH rALL-18 PROTOCOL) — experience from Tata Memorial Hospital, India;Annals of Hematology;2023-07-21

4. Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies;Pediatric Blood & Cancer;2023-04-10

5. Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group;Pediatric Blood & Cancer;2022-09-09